Neil K. Warma, President & CEO, Opexa Therapeutics, gives background on what he means by “personalized therapy”. In contrast to the “sledgehammer effect” that current oral multiple sclerosis (MS) have on immune systems, Opexa’s precision T-cell immunotherapy, Tcelna, selectively targets only the pathogenic T-cells. 3 Steps to Personalized Therapy for MS 1) Blood sample collected at local Red Cross 2) Identify the specific myelin antigens to which the T-cells bind 3) Manufacture a unique T-cell vaccine tailored to the patient’s profile